Compare ALLO & CHMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALLO | CHMG |
|---|---|---|
| Founded | 2017 | 1833 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.6M | 415.9M |
| IPO Year | 2018 | 1995 |
| Metric | ALLO | CHMG |
|---|---|---|
| Price | $0.76 | $83.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | $9.00 | ★ $92.35 |
| AVG Volume (30 Days) | ★ 11.2M | 48.8K |
| Earning Date | 11-05-2026 | 10-22-2026 |
| Dividend Yield | N/A | ★ 1.73% |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ 6.36 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $31.95 |
| Revenue Next Year | $72.02 | $7.35 |
| P/E Ratio | ★ N/A | $13.10 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $50.31 |
| 52 Week High | $4.46 | $89.34 |
| Indicator | ALLO | CHMG |
|---|---|---|
| Relative Strength Index (RSI) | 21.26 | 45.29 |
| Support Level | N/A | $79.30 |
| Resistance Level | $2.25 | $84.69 |
| Average True Range (ATR) | 0.10 | 2.02 |
| MACD | -0.02 | -0.32 |
| Stochastic Oscillator | 0.42 | 4.31 |
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.